Login Register Cart 0
Research Article

非靶向代谢组学提供了对耐药高血压机制的深入了解。

卷 26, 期 1, 2019

页: [232 - 243] 页: 12

弟呕挨: 10.2174/0929867324666171006122656

open access plus

摘要

背景：在全世界接受治疗的高血压患者中，抗高血压（RH）的发病率约为15-20%。相对湿度增加心血管事件的风险，如心肌梗死和中风50%。对治疗抵抗的病理机制仍知之甚少。 目的：本初步研究的主要目的是确定和比较耐药和非耐药高血压患者的血浆代谢特征。 方法：对69例rh患者和81例控制性高血压患者的血浆进行非靶向代谢谱分析。为了确定患者对降压治疗的依从性，采用LC-ESI-TOF/MS技术测定血浆样品中所选药物及其代谢产物的水平。 结果：两组的降压药给药无统计学差异。我们在rh中鉴定了19种上调和13种下调的代谢物。 结论：Rh代谢产物的改变与氧化应激和炎症、内皮功能紊乱、血管收缩和细胞增殖有关。我们的结果可能会产生关于相对湿度发展和进展的新假设。

关键词: 抗高血压，代谢组学，液相色谱，质谱，多变量分析，生物标志物候选。

« Previous Next »
[1]
Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: analysis of worldwide data. Lancet, 2005, 365, 217-223.
[2]
Achelrod, D.; Wenzel, U.; Frey, S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am. J. Hypertens., 2015, 28, 355-361.
[3]
Calhoun, D.A.; Jones, D.; Textor, S.; Goff, D.C.; Murphy, T.P.; Toto, R.D.; White, A.; Cushman, W.C.; White, W.; Sica, D.; Ferdinand, K.; Giles, T.D.; Falkner, B.; Carey, R.M. American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 2008, 117, 510-526.
[4]
Sarafidis, P.A.; Georgianos, P.; Bakris, G.L. Resistant hypertension its identification and epidemiology. Nat. Rev. Nephrol., 2013, 9, 51-58.
[5]
Daugherty, S.L.; Powers, J.D.; Magid, D.J.; Tavel, H.M.; Masoudi, F.A.; Margolis, K.L.; O’Connor, P.J.; Selby, J.V.; Ho, P.M. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation, 2012, 125, 1635-1642.
[6]
Williams, B. Resistant hypertension: an unmet treatment need. Lancet, 2009, 374, 1296-1298.
[7]
MacMahon, S.; Peto, R.; Cutler, J.; Collins, R.; Sorlie, P.; Neaton, J.; Abbott, R.; Godwin, J.; Dyer, A.; Stamler, J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 1990, 335, 765-774.
[8]
Zheng, Y.; Yu, B.; Alexander, D.; Mosley, T.H.; Heiss, G.; Nettleton, J.A.; Boerwinkle, E. Metabolomics and incident hypertension among blacks: the atherosclerosis risk in communities study. Hypertension, 2013, 62, 398-403.
[9]
Menni, C.; Mangino, M.; Cecelja, M.; Psatha, M.; Brosnan, M.J.; Trimmer, J.; Mohney, R.P.; Chowienczyk, P.; Padmanabhan, S.; Spector, T.D.; Valdes, A.M. Metabolomic study of carotid-femoral pulse-wave velocity in women. J. Hypertens., 2015, 33, 791-796.
[10]
Kordalewska, M.; Markuszewski, M.J. Metabolomics in cardiovascular diseases. J. Pharm. Biomed. Anal., 2015, 113, 121-136.
[11]
Schanckenberg, L.K.; Beger, R.D. Metabolomic biomarkers: their role in the critical path. Drug Discov. Today. Technol., 2007, 4, 13-16.
[12]
Ciborowski, M.; Lipska, A.; Godzien, J.; Ferrarini, A.; Korsak, J.; Radziwon, P.; Tomasiak, M.; Barbas, C. Combination of LC−MS- and GC−MS-based metabolomics to study the effect of ozonated autohemotherapy on human blood. J. Proteome Res., 2012, 11, 6231-6241.
[13]
Warrack, B.M.; Hnatyshyn, S.; Ott, K.H.; Reily, M.D.; Sanders, M.; Zhang, H.; Drexler, D.M. Normalization strategies for metabonomic analysis of urine samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 15, 547-552.
[14]
Dunn, W.B.; Broadhurst, D.; Begley, P.; Zelena, E.; Francis-McIntyre, S.; Anderson, N.; Brown, M.; Knowles, J.D.; Halsall, A.; Haselden, J.N.; Nicholls, A.W.; Wilson, I.D.; Kell, D.B.; Goodacre, R. Human Serum Metabolome (HUSERMET) Consortium. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc., 2011, 6, 1060-1083.
[15]
Jimenez-Contreras, E.; Torres-Salinas, D.; Moreno, R.; Banos, R.; Lopez-Cozar, E. Response Surface Methodology and its application in evaluating scientific activity. Scientometrics, 2009, 79, 201-218.
[16]
Farrell, E.K.; Chen, Y.; Barazanji, M.; Jeffries, K.A.; Cameroamortegui, F.; Merkler, D.J. Primary fatty acid amide metabolism: conversion of fatty acids and an ethanolamine in N 18 TG 2 and SCP cells 1. J. Lipid Res., 2012, 53, 247-256.
[17]
Hopps, J.J.; Dunn, W.R.; Randall, M.D. Enhanced vasorelaxant effects of the endocannabinoid-like mediator, oleamide, in hypertension. Eur. J. Pharmacol., 2012, 684, 102-107.
[18]
Ciborowski, M.; Martin-Ventura, J.L.; Meilhac, O.; Michel, J.B.; Ruperez, F.J.; Tunon, J.; Egido, J.; Barbas, C. Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. J. Proteome Res., 2011, 10, 1374-1382.
[19]
Ren, R.; Hashimoto, T.; Mizuno, M.; Takigawa, H.; Yoshida, M.; Azuma, T.; Kanazawa, K. A lipid peroxidation product 9-oxononanoic acid induces phospholipase A2 activity and thromboxane A2 production in human blood. J. Clin. Biochem. Nutr., 2013, 5, 228-233.
[20]
Pop, D.; Sitar-Tǎut, A.; Bodisz, G.; Zdrenghea, D.; Cebanu, M.; Stanca, L. Role of secretory phospholipase A2 in women with metabolic syndrome. Indian J. Med. Res., 2013, 138, 866-872.
[21]
Ding, Y.; Wu, C.C.; Garcia, V.; Dimitrova, I.; Weidenhammer, A.; Joseph, G.; Zhang, F.; Manthati, V.L.; Falck, J.R.; Capdevila, J.H.; Schwartzman, M.L. 20-HETE induces remodeling of renal resistance arterie independent of blood pressure elevation in hypertension. Am. J. Physiol. Renal Physiol., 2013, 305, 53-63.
[22]
Claire, M.; Jacotot, B.; Robert, L. Characterization of lipids associated with macromolecules of the intercellular matrix of human aorta. Connect. Tissue Res., 1976, 4, 61-71.
[23]
Bartke, N.; Hannun, Y.A. Bioactive sphingolipids: metabolism and function. J. Lipid Res., 2009, 50, 91-96.
[24]
Wu, Q.; Zhang, H.; Dong, X.; Chen, X-F.; Zhu, Z-Y.; Hong, Z-Y.; Chai, Y-F. UPLC-Q-TOF/MS based metabolomic profiling of serum and urine of hyperlipidemic rats induced by high fat diet. J. Pharm. Anal., 2014, 4, 360-367.
[25]
Pavoine, C.; Pecker, F. Sphingomyelinases: Their regulation and roles in cardiovascular pathophysiology. Cardiovasc. Res., 2009, 82, 175-183.
[26]
Thijs, L.; Fagard, R.; Forette, F.; Nawrot, T.; Staessen, J.A. Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies. Acta Cardiol., 2003, 58, 403-410.
[27]
Nikolic, S.B.; Sharman, J.E.; Adams, M.J.; Edwards, L.M. Metabolomics in hypertension. J. Hypertens., 2014, 32, 1159-1169.
[28]
Mitchell, B.M.; Dorrance, A.M.; Webb, R.C. Phenylalanine improves dilation and blood pressure in GTP cyclohydrolase inhibition-induced hypertensive rats. J. Cardiovasc. Pharmacol., 2004, 43, 758-763.
[29]
Pelley, J.W.; Goljan, E.F. Rapid Review Biochemistry: With student consult, 3rd ed; Elsevier: Philadelphia, 2011.
[30]
Sakurai, H. Urate transporters in the genomic era. Curr. Opin. Nephrol. Hypertens., 2013, 22, 545-550.
[31]
Mazzali, M.; Kanbay, M.; Segal, M.S.; Shafiu, M.; Jalal, D.; Feig, D.I.; Johnson, R.J. Uric acid and hypertension: Cause or effect? Curr. Rheumatol. Rep., 2010, 12, 108-117.
[32]
Feig, D.I. The role of uric acid in the pathogenesis of hypertension in the young. J. Clin. Hypertens., 2012, 14, 346-352.

Rights & Permissions Print Cite
Article Metrics
98
9
© 2024 Bentham Science Publishers | Privacy Policy